BIOTON S.A. Stock price

Equities

BIO

PLBIOTN00029

Biotechnology & Medical Research

Market Closed - Warsaw S.E. 12:55:40 2024-03-28 pm EDT 5-day change 1st Jan Change
3.57 PLN +1.71% Intraday chart for BIOTON S.A. +0.56% 0.00%
Sales 2021 163M 40.8M Sales 2022 233M 58.35M Capitalization 289M 72.41M
Net income 2021 2M 500K Net income 2022 1M 250K EV / Sales 2021 2.82 x
Net Debt 2021 101M 25.33M Net Debt 2022 67.05M 16.78M EV / Sales 2022 1.53 x
P/E ratio 2021
140 x
P/E ratio 2022
204 x
Employees 357
Yield 2021 *
-
Yield 2022
-
Free-Float 40.31%
More Fundamentals * Assessed data
Dynamic Chart
BIOTON S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
BIOTON S.A. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
BIOTON S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
BIOTON S.A. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
BIOTON S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
BIOTON S.A. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
BIOTON S.A. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
BIOTON S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
Bioton S.A. Reports Earnings Results for the Half Year Ended June 30, 2021 CI
Bioton S.A. Reports Earnings Results for the First Quarter Ended March 31, 2021 CI
Yifan Pharmaceutical Co., Ltd. completed the acquisition of 19.79% stake in BIOTON S.A. from Ningbo Free Trade Zone Dongren Investment Co., Ltd. CI
Yifan Pharmaceutical Co., Ltd. completed the acquisition of 11.86% stake in BIOTON S.A. from Kelipond Investment Limited. CI
Yifan Pharmaceutical Co., Ltd. signed an agreement to acquire 11.86% stake in BIOTON S.A. from Kelipond Investment Limited for approximately CNY 270 million. CI
Yifan Pharmaceutical Co., Ltd. agreed to acquire 19.79% stake in BIOTON S.A. from Ningbo Free Trade Zone Dongren Investment Co., Ltd. for approximately CNY 450 million. CI
YiFan International Pharmaceutical Co., Limited completed the acquisition of SciGen Ltd from BIOTON S.A. and others. CI
More news
1 day+1.71%
1 week+0.56%
Current month-1.65%
1 month-1.38%
3 months+1.13%
6 months-7.15%
More quotes
1 week
3.30
Extreme 3.3
3.58
1 month
3.30
Extreme 3.3
3.63
Current year
3.30
Extreme 3.3
3.78
1 year
3.30
Extreme 3.3
4.10
3 years
3.26
Extreme 3.26
6.18
5 years
2.00
Extreme 2
7.82
10 years
2.00
Extreme 2
17.35
More quotes
Managers TitleAgeSince
Chief Executive Officer - 20-10-29
Director of Finance/CFO - 18-08-31
Chief Administrative Officer - 16-12-31
Members of the board TitleAgeSince
Director/Board Member - 21-12-31
Director/Board Member 51 21-12-31
Director/Board Member - 19-12-02
More insiders
Date Price Change Volume
24-03-28 3.57 +1.71% 50,686
24-03-27 3.51 -1.68% 16,594
24-03-26 3.57 0.00% 13,635
24-03-25 3.57 +0.56% 56,685
24-03-22 3.55 0.00% 81,133

Delayed Quote Warsaw S.E., March 28, 2024 at 12:55 pm EDT

More quotes
Bioton SA is a Poland-based company active in the pharmaceutical sector. The Company is engaged in research, development and wholesale trade of pharmaceutical and biotechnological products. The Company's portfolio consists of oral hypoglycemic drugs (metformin and glimepride) as well as recombinant human insulin in pharmaceutical substance form and for injections. Additionally, the Company provides advertising services. As of December 31, 2011, the Company formed a capital group and operated through its subsidiaries, including BIOTON TRADE Sp. z o.o., Mindar Holdings Ltd, Germonta Holdings Ltd, Tricel SA, SciGen Ltd and BioPartners Holdings AG, among others. On June 12, 2014, it sold a 50% stake in Copernicus Sp. z o.o.
More about the company
  1. Stock
  2. Equities
  3. Stock BIOTON S.A. - Warsaw S.E.